Veeva Systems Inc (VEEV)
SurévaluéFondamental
76
Prix
$284.18
Capitalisation boursière
$45.33B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$3.46B
12 derniers mois (au 31/07/2026)
Résultat net
$1.01B
12 derniers mois (au 31/07/2026)
Flux de trésorerie libre
-
Capitaux propres totaux
$7.21B
Passif total
$1.76B
Ratio de liquidité général
5.46
Couverture des intérêts
-
Dette/EBITDA
0.14
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$192.90
Prix actuel
$284.18
Marge de sécurité
-47.3%
Fourchette de juste valeur
$125.39 - $260.42
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
46.72
ROE
12.6%
Ratio P/B
6.22
P/FCF
-
Marge brute
75.0%
ROIC
10.8%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
10.8%
WACC
9.5%
ROIC − WACC
+1.3 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (19)
- EPS shows upward trend
- EPS CAGR 49.24%
- Price CAGR 20.49%
- ROIC 10.8%
- Gross Margin 75.0%
- Debt/Equity ratio
- Operating Margin 29.9%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 14.0%
- Revenue Growth 5Y 16.9%
- Analyst Consensus 72% Buy
- Earnings Surprise avg 3.4%
- Earnings Quality (OCF/NI) 1.64
- Share Dilution 1.1%
- Net Margin Trend 29.3% vs 27.3%
- Piotroski F-Score 7/9
Échoué (4)
- P/B Ratio 6.22
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 2.46
Indisponible (5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Peter P. Gassner | Founder, CEO & Director | 60 |
| Ms. Eleni Nitsa Zuppas | President & Chief of Staff | 55 |
| Mr. Thomas D. Schwenger | President & Chief Customer Officer | 57 |
| Mr. Brian Van Wagener | Chief Financial Officer | 42 |
| Mr. Jonathan W. Faddis J.D. | Senior VP, General Counsel & Corporate Secretary | 53 |
| Mr. Vipin Kondath | Chief Accounting Officer | 49 |
| Ms. Catherine Allshouse | Chief Information Officer | - |
| Mr. Gunnar Georg Hansen | Director of Investor Relations | - |
| Ms. Vivian Welsh | Chief People Officer | - |
| Mr. Paul Shawah | Executive Vice President of Strategy & Campaign Manager | - |
Risque d'audit
2
Risque du conseil
8
Risque de rémunération
10
Risque droits des actionnaires
9
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-03-20
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-27
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-08-26
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for VEEV, sourced from Markets Gazette.
- 6/4/2026POSITIVEVeeva Rides AI Wave As Pharma Cloud Story Accelerates
Veeva Systems Inc. has announced a first-quarter earnings beat and subsequently raised its full-year guidance, signaling strong operational performance and positive future outlook. Analysts have responded favorably, maintaining their 'Buy' ratings and highlighting the company's strategic initiatives in Artificial Intelligence (AI) as a key growth driver. This news suggests that Veeva's cloud-based solutions for the pharmaceutical industry are gaining traction, further enhanced by its AI capabilities. Investors should note the upward revision in guidance and sustained analyst confidence, which could translate into continued stock appreciation.
- 5/11/2026POSITIVEHere's How Much You Would Have Made Owning Veeva Systems Stock In The Last 10 Years
Veeva Systems stock has delivered exceptional returns over the past decade, with an investment of $1,000 in May 2016 now valued at approximately $12,000 as of May 2026. This represents a staggering 1100% gain, significantly outperforming the broader market. The company, a leader in cloud-based software for the life sciences industry, has consistently grown its revenue and earnings, driven by strong customer adoption and expansion of its product offerings. Investors have rewarded this consistent performance, making Veeva Systems a standout performer in the technology sector.
- 5/8/2026POSITIVE$100 Invested In Veeva Systems 10 Years Ago Would Be Worth This Much Today
An investment of $100 in Veeva Systems (VEEV) a decade ago would have grown substantially, highlighting the company's robust long-term performance. While specific figures for the current valuation are not provided in this snippet, the implication of significant growth suggests strong revenue expansion and profitability over the past ten years. This historical performance indicates effective business strategy and market positioning, potentially signaling continued positive outlook for investors.
- 5/1/2026POSITIVEThe S&P 500’s newest member is this under-the-radar software stock
Veeva Systems Inc. is set to join the S&P 500 index, a move that typically boosts investor sentiment and stock performance. The inclusion signifies the company's substantial growth and market capitalization, making it a more prominent player in the large-cap equity space. For investors, this event often leads to increased institutional buying as index-tracking funds rebalance their portfolios. The stock's 'soaring' performance ahead of the official inclusion suggests strong market anticipation and confidence in Veeva's future prospects within the benchmark index.
- 3/14/2026NEUTRALIs Veeva Systems a Multimillionaire-Maker Stock?
Veeva Systems Inc. has started its journey with a 'pretty decent' performance, as indicated by the provided news snippet. While specific financial metrics or growth drivers are not detailed, this initial assessment suggests the company is meeting or slightly exceeding expectations in its early stages. Investors often look for such steady beginnings as a sign of potential long-term stability and growth. Further analysis would be required to determine if this initial momentum translates into significant shareholder value, but the neutral tone suggests no immediate cause for concern or excitement.
- 3/5/2026NEUTRALVeeva (VEEV) Q4 2026 Earnings Call Transcript
The Q4 2026 earnings call transcript for Veeva Systems Inc. (VEEV) has been released. While the specific content of the call is not available at this time, the release of an earnings transcript is a standard event for publicly traded companies. Investors typically analyze these documents to assess financial performance, future outlook, and corporate strategies. Without specific details, the impact on VEEV stock remains neutral, pending a thorough analysis of the call's content for any positive or negative signals.
- 2/23/2026POSITIVE1 Reason I'd Buy Veeva Systems Stock and Never Sell
A market analysis highlights Veeva Systems as a compelling long-term investment opportunity, advocating a "buy and never sell" strategy. The primary reason lies in its dominant, near-monopolistic position in the cloud software sector for the life sciences and pharmaceutical industries. With its product suite, including Veeva Vault and Veeva CRM, the company has built an integrated ecosystem that creates high switching costs for its clients, ensuring a predictable and recurring revenue stream. Despite potential short-term market fluctuations, the company's solid fundamentals and deep competitive moat make the stock particularly attractive for investors with an extended time horizon. Customer loyalty and vertical business specialization are seen as the pillars of sustainable, long-lasting growth.
via Markets Gazette